Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 4, 2025International Journal of GenomicsOpen Access

Sphingolipid Metabolism Dysregulation Drives Immune Microenvironment Remodeling and Predicts Prognosis in Bladder Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

ZPZechun PengJYJie YangRJRuipeng Jia

Discussion

Loading...

Member takes

Overview

Analysis reveals sphingolipid metabolism impacts bladder cancer outcomes, suggesting immunomodulatory changes serve as therapeutic targets.

Key Points

  • Therapeutic targets identified were linked to poor outcomes in bladder cancer patients, indicating potential intervention points for treatment.
  • Multivariable Cox regression analysis produced a risk model achieving AUC values of 0.772 and 0.725 in training and validation cohorts respectively.
  • Eight significant prognostic genes associated with sphingolipid metabolism were found to correlate with immunological changes in tumorous environments.
  • Biomarker tools developed from these insights are positioned for implementation in personalized risk stratification for bladder cancer patients.

Cite This Study

Peng et al. (2025) studied this question.

synapsesocial.com/papers/690945348f2297dc1353302ahttps://doi.org/10.1155/ijog/6085216
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analyzing the Impact of Sphingolipid Metabolism Genes on bladder cancer Progression and Microenvironment for the Development of a Prognostic Signature2024
  2. 2Prognostic Value of Preoperative Albumin-to-Alkaline Phosphatase Ratio in Patients with Muscle-Invasive Bladder Cancer After Radical Cystectomy2020 · 13 citations
  3. 3Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics2017 · 45 citations
  4. 4A Consensus Molecular Classification of Muscle-invasive Bladder Cancer2019 · 1,413 citations
  5. 5Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer2019 · 49 citations